Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks – SOBRsafe Inc. (NASDAQ: SOBR) Secures Nasdaq Compliance, Continues Listing Under Monitoring Period

SOBRsafe (NASDAQ: SOBR) announced its compliance with Nasdaq’s listing standards, meeting minimum bid price, public float, and stockholders’ equity requirements per the August 2024 Nasdaq Hearings Panel decision. As a result, SOBRsafe’s common stock will remain listed on the Nasdaq Capital Market. The company will undergo a one-year monitoring period starting Oct. 30, 2024, during which any recurrence of non-compliance with the stockholders’ equity rule will result in an immediate Delist Determination Letter, requiring a new hearing request without a compliance grace period.

To view the full press release, visit https://ibn.fm/MX9lm

About SOBRsafe(TM)

Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe(TM), where advanced transdermal (touch-based) technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin – no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next-generation, passive detection technology for the behavioral health, judicial and consumer markets, and for licensing and integration. The SOBRsafe technology is commercially available for point-of-care screening (“SOBRcheck”) and continuous monitoring (“SOBRsure”). SOBRsafe is creating a culture of prevention and support. To learn more, visit www.SOBRsafe.com.

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in SOBRsafe Inc. SOBR | Leave a comment

MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q3 Earnings Call with Key Regulatory and Initiative Updates

HeartBeam (NASDAQ: BEAT), a medical technology company focused on enhancing cardiac care through advanced insights, will hold a conference call on November 7, 2024, at 4:30 p.m. ET to discuss third-quarter results and share updates on regulatory developments and ongoing projects. CEO Robert Eno, Founder and President Dr. Branislav Vajdic, and CFO Timothy Cruickshank will lead the call, which will include a Q&A session and a presentation accessible via the company’s investor relations page. A press release with detailed Q3 results will be released prior to the call.

To view the full press release, visit https://ibn.fm/yqTng

About HeartBeam Inc.

HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com .

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in HeartBeam Inc. BEAT | Leave a comment

MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Details Promising Phase 3 Path for Alzheimer’s Treatment on The BioMedWire Podcast

Annovis Bio (NYSE: ANVS) led by Founder, President and CEO Dr. Maria Maccecchini, shares exciting developments regarding its pioneering Alzheimer’s and Parkinson’s drug candidate, buntanetap. In her interview on IBN’s BioMedWire Podcast, Dr. Maccecchini discusses Annovis Bio’s recent FDA clearance to proceed with pivotal Phase 3 trials for early-stage Alzheimer’s patients, a critical step toward potential market approval. Highlighting buntanetap’s unique mechanism that targets multiple neurotoxic proteins, Dr. Maccecchini explains the potential for superior outcomes compared to existing therapies, emphasizing the drug’s demonstrated short-term efficacy and differentiated approach in neurodegenerative treatment.

To view the full press release, visit https://ibn.fm/bjoc8

About Annovis Bio Inc.

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Annovis Bio Inc. ANVS | Leave a comment

MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to Patients

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering novel therapies for neurodegenerative diseases. Recent clinical trials of the company’s lead compound yielded encouraging results, with buntanetap shown to improve cognition in both Alzheimer’s and Parkinson’s patients. The company also introduced a new crystalline form of buntanetap with improved properties, “offering significant advantages over the less structured, old semi-crystalline form,” according to a recent article.

“Annovis filed the new crystalline form with the International Patent Cooperation Treaty and a provisional patent for the manufacturing of this crystalline form, covering the entire synthesis process. The company also received approval from the Food and Drug Administration to continue the clinical development with this new form of buntanetap. Additionally, the company was granted a U.S. patent for the use of buntanetap in the treatment of acute traumatic brain injury, expanding its coverage, since acute indication claims had been previously granted in Europe and worldwide,” the article reads. “These milestones position us strongly as we move closer to providing much-needed treatments to patients,” said Annovis Bio Founder, President and CEO Maria L. Maccecchini, Ph.D.

To view the full article, visit https://ibn.fm/26DK1

About Annovis Bio Inc.

Headquartered in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Annovis Bio Inc. ANVS | Leave a comment

Tiny Island in the Caribbean Gets Windfall as AI Boom Gathers Steam

While it is common knowledge that investors in tech firms like Nvidia Corp. (NASDAQ: NVDA) are accumulating fortunes from AI, the island of Anguilla is also minting serious cash from this industry. This started at about the time ChatGPT went public and set off a frenzy among companies wishing to get websites ending in .ai.

Cue in Anguilla. This British territory in the Caribbean didn’t know it had struck future gold when, by a stroke of luck, it was allocated the .ai internet address back in 1995. Each country has a unique internet address for sites located within its jurisdiction, and Anguilla found itself with the .ai address for its internet traffic. It should be noted that it isn’t compulsory for a website to contain the internet initials of the country where it is domiciled, but many still include that address as part of the website address.

So, Anguilla got the right address, but the good tidings came decades later. At the moment, many companies are rushing to include .ai in their website addresses, and given that Anguilla is the legal holder of those initials, it is reaping from its good fortune. For example, Google is currently using google.ai as a way to showcase the AI services it offers, just as x.ai is the address for the chatbot Grok offered by Tesla owner Elon Musk.

In the same vein, Perplexity, a startup bent on taking as big a cut of search traffic from Google as it can, also owns an .ai address. Many companies also have such addresses, and many more are in the process of acquiring them in order to tell site visitors right off the bat that they are in the business of providing services leveraging artificial intelligence.

Anguilla is earning money fist over fist as the modern “gold rush” plays out. The country is paid for each domain that is registered with the .ai initial at its end. This revenue quadruped to $32m in 2023. On the surface, this figure may not be ground-shaking, but it now accounts for a significant 20% of the government’s revenue. Prior to the boom in AI, the fraction hovered at approximately 5%. The country also gets paid each time one of these domains is renewed.

Demand for sites with this ending has skyrocketed to the extent that the government of Anguilla has contracted Identity Digital, an American-based firm also hired by Australia, to manage this domain registration and renewal process. The domains are so much in demand that some have been sold at multiples of $10,000!

This island, which is famous for its premium tourist attractions (clear waters, coral reefs and white sand beaches teeming with palm trees) favored by the ultra-wealthy as a holiday destination, is using this uptick in revenue to expand the country’s airport, provide free healthcare services to the elderly, and also complete a tech training institution on the island.

Amidst the frenzy of the AI boom, much of the spotlight remains on tech giants and trailblazing innovators. Yet, underpinning this high-tech revolution are essential “workhorse metals”—silver, gold, and copper—that make the infrastructure for AI possible, from advanced graphics processors to expansive data centers. Companies like McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) that focus on mining these critical metals are positioned to benefit from AI’s burgeoning demand. Just as fortunes were made by supplying shovels during the California Gold Rush, today’s mining companies play a pivotal role by providing the foundational resources that fuel the AI industry.

For more information, visit the company’s website at www.McEwenMining.com

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in McEwen Mining Inc. MUX | Leave a comment

Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Eyeing Response to U.S. Recommendation to Impose Sanctions on Russian Titanium, Palladium

  • The Biden administration aims to weaken Russia’s financial stability through sanctions, limiting its ability to sustain its war efforts in Ukraine.
  • Imposing sanctions on Russian titanium and palladium would create several strategic advantages for the U.S.
  • Sanctions on Russian palladium and titanium could be especially advantageous for existing producers and emerging palladium mining projects outside of Russia.

The United States recently called on its Group of Seven (“G7”) allies to consider imposing sanctions on Russian titanium and palladium supplies, a move that, if approved, could have a profound impact on global metals markets as well as on Russia’s economy (https://ibn.fm/Q9sHS). Companies operating in the metals sector, including Platinum Group Metals (NYSE American: PLG) (TSX: PTM), majority owner and operator of the Waterberg PGM Project in South Africa, are watching closely to see what action the G7 might take.

“Biden administration officials floated the [sanction] possibility during a meeting of G7 deputy finance ministers on Tuesday in Washington,” a Bloomberg article reported. “Finance officials from around the world have gathered in the U.S. capital for annual meetings of the International Monetary Fund and the World Bank. The Biden administration aims to weaken Russia’s financial stability further, limiting its ability to sustain its war efforts in Ukraine. 

“Sanctions targeting these specific metals would strategically restrict Russia’s economic inflow from two of its major exports, as titanium is essential for the aerospace and medical sectors, while palladium is critical in automotive, electronics and tech manufacturing,” the article continued. “One major challenge is that Europe is reliant on the metals and has shown little appetite to target them in the past. G7 members Germany, France and Italy would also need the backing of the other 24 members of the European Union for such sanctions.”

If G7 sanctions materialize, Russian companies, which currently dominate global palladium production and control a significant portion of the titanium market, would face restricted access to the international marketplace. This change would diminish Russia’s export revenue and limit its resources, directly impacting its ability to finance military operations.

Sanctions on Russian palladium could be particularly advantageous for non-Russian producers and emerging mine developers such as Platinum Group Metals Ltd. operator of the Waterberg PGM Project. PGMs are critical for pollution control in the automotive sector, including traditional internal combustion engines (“ICE”) and the growing gasoline hybrid and plug-in hybrid (“PHEV”) segments. PGMs also play a critical role in fuel-cell technology and the production of hydrogen.

For more information, visit www.PlatinumGroupMetals.net.

NOTE TO INVESTORS: The latest news and updates relating to PLG are available in the company’s newsroom at https://ibn.fm/PLG

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Platinum Group Metals Ltd. PLG | Leave a comment

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX): Tapping into Argentina’s Growing Copper Potential

Argentina is rapidly emerging as a key player in the global mining industry, positioning itself to become a significant producer of copper and other minerals critical to the world’s clean energy transition. The country’s ambition to rank among the top ten copper producers by 2030 reflects its immense potential, driven by vast untapped mineral reserves, recent policy reforms, and a growing pipeline of mining projects.

Currently, Argentina holds an estimated 75.5 million metric tons of copper reserves, representing about 3% of the global total (https://ibn.fm/XkBiO). Although this is modest compared to copper giants like Chile and Peru, Argentina’s improving investment climate and regulatory changes suggest it could soon become a global hotspot for mining development.

One of the most pivotal factors in this shift is Argentina’s new Incentive Regime for Large Investments (“RIGI”), which introduces significant tax breaks and eases capital controls for foreign investors. By offering tax incentives, reducing income and dividend taxes, and ensuring long-term regulatory stability, the RIGI program is addressing long-standing issues that have hampered the sector. These reforms are attracting substantial foreign investment in copper, gold and lithium exploration, creating an investor-friendly environment that is vital for fueling the country’s mining growth.

Argentina’s wealth of undeveloped copper deposits, particularly in the Andean region, positions the country as a potential solution to bridge the global supply gap as demand for copper continues to rise. Government forecasts predict Argentina could produce up to 793,000 metric tons of copper annually by 2030 (https://ibn.fm/OiwZJ), placing it alongside major producers like Australia and Zambia. With over $22 billion in capital expenditure allocated across multiple copper projects, Argentina is poised to become a significant player in global mining.

McEwen Mining: Seizing Argentina’s Copper Potential

Among the key companies capitalizing on Argentina’s mining opportunity is McEwen Mining (NYSE: MUX) (TSX: MUX), an established producer of gold and silver with operations across Nevada, Canada, Mexico, and Argentina. Founded by industry veteran Rob McEwen who serves as Chairman and Chief Owner, the company’s strategic advantage lies in its significant exposure to copper through its 46.4%-owned subsidiary, McEwen Copper.

The centerpiece of McEwen Copper’s portfolio is the Los Azules project, located in San Juan, Argentina. This massive copper deposit is currently ranked as the 8th largest undeveloped copper resource globally. As the global shift towards renewable energy and advanced technologies accelerates, the demand for copper—essential for electrical systems and data centers—is expected to continue rising. Los Azules, with its immense copper reserves, holds enormous strategic importance for McEwen Copper.

Los Azules: A Project with Tremendous Potential

Recent drilling results have reinforced Los Azules’ economic viability, revealing high-grade copper mineralization. Notable highlights include:

  • 217 meters of 1.11% copper, including 100 meters of 1.32% copper
  • 158 meters of 0.84% copper, including 78.5 meters of 1.10% copper
  • 276 meters of 0.86% copper, including 160 meters of 0.96% copper

These results underscore the tremendous potential of the project, which could significantly boost McEwen Copper’s value.

Commitment to Sustainability

In addition to its resource strength, McEwen Copper has demonstrated a commitment to sustainability through its partnership with YPF Luz (https://ibn.fm/63FoQ), Argentina’s leading renewable energy provider. Under this agreement, Los Azules will be powered entirely by renewable energy, positioning the project as a model of responsible mining. This aligns with global decarbonization efforts and enhances its appeal to environmentally conscious investors.

Michael Meding, VP of McEwen Copper, has emphasized the project’s crucial role in decarbonization, while YPF Luz’s CEO, Martín Mandarano, praises the collaboration as a forward-thinking solution for sustainable copper production. This partnership highlights McEwen Copper’s forward-looking approach to mining.

Continued Investment from Rio Tinto’s Nutron

The recent announcement of an additional $35 million investment by Nuton, a Rio Tinto venture, into McEwen Copper marks the latest milestone. Nuton’s acquisition of 1,166,666 common shares at $30.00 per share not only underscores the strategic importance of the Los Azules project but also enhances McEwen Copper’s financial capacity to advance its feasibility study, which is expected to be completed in the first half of 2025.

With this investment, Nuton now holds a 17.2% stake in McEwen Copper, joining other major stakeholders like McEwen Mining Inc. (46.4%), Stellantis (18.3%), and Rob McEwen himself (12.7%). This strategic partnership aligns with Argentina’s growing prominence in the global copper industry, supported by favorable investment policies and a wealth of untapped mineral resource.

Building on Continued Success

With its diversified asset base, McEwen Mining is well-positioned to capitalize on rising global demand for critical minerals like copper, gold and silver. The Los Azules copper project provides a strong foundation for future growth, while the company’s commitment to sustainability and strategic partnerships reinforces its long-term value proposition.

Rob McEwen has been associated with the gold industry all his career, with his first 18 years in the investment industry and, since 1990, as CEO of several gold mining companies. He founded Goldcorp and took that company from a $50 million market capitalization to more than $8 billion. He owns 17% of McEwen Mining and is in complete alignment with investors – his investment in MUX and McEwen Copper is more than $225 million and he takes an annual salary of only $1.

Under Rob’s proven leadership, McEwen Mining is an intriguing investment opportunity. Its copper exposure in Argentina, combined with its gold and silver operations across the Americas, positions the company as a key player in the global mining sector—especially as Argentina emerges as a prominent resource-rich landscape.

For more information, visit the company’s website at www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in McEwen Mining Inc. MUX | Leave a comment

Annovis Bio Inc. (NYSE: ANVS) Gets FDA Clearance for Buntanetap Pivotal Phase 3 Trials, Market Enthusiasm Highlighted in GuruFocus Article

  • Financial research platform GuruFocus underlines Annovis’ unique approach to tackling neurodegenerative conditions such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”).
  • The FDA’s decision to allow the company to go to Phase 3, points to the fact that lead drug candidate buntanetap may be an effective treatment for AD, one of the most critical diseases in an aging society.
  • Buntanetap has been shown to significantly improve cognition in early AD patients, both by itself or on top of existing therapies.
  • The Phase 3 program will consist of two trials: a 6-month study aimed at confirming buntanetap’s symptomatic benefits and an 18-month study to explore potential disease-modifying effects.
  • Annovis plans to initiate the first trial in Q1 2025, with the possibility of submitting an NDA based on the completion of the 6-month study.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently secured the approval of the U.S. Food and Drug Administration (“FDA”) to pursue Phase 3 clinical trials for lead Alzheimer’s drug candidate buntanetap. This important milestone, along with recent stock developments and the company’s likely future, were highlighted in an article on financial research platform GuruFocus (https://ibn.fm/Aek2Z).

“The market is enthusiastic to Annovis Bio, Inc. and some say that they tackle Alzheimer’s and Parkinson’s in ways humanity has never achieved before,” the article says, emphasizing that buntanetap was reported to do well in Phase 2a and 2/3 trials, indicating improvement in Alzheimer’s patients.

“The FDA’s action to allow the company to go to Phase 3 is a positive point to the fact that buntanetap may be an effective cure for this disease that ravages the lives of so many people,” the article also says.

The GuruFocus piece also underlines that the future of Annovis is wide open because its drug targets Alzheimer’s and other neurodegenerative diseases that affect millions of families in the U.S. and worldwide.

Buntanetap works by lowering levels of multiple neurotoxic proteins that are responsible for multiple pathways involved in neurodegenerative diseases. A recent Phase 2/3 study showed that buntanetap exhibited significant cognitive improvements in early Alzheimer’s patients, while maintaining a strong safety profile. This trial involved 353 patients and assessed buntanetap’s efficacy and safety on top of standard-of-care medications. Study results showed a 3.3-point improvement on the ADAS-Cog11 test after three months of treatment, compared to a 0.3-point improvement in the placebo group.

After a successful end-of-Phase 2 meeting with the FDA, the company was cleared to start two pivotal Phase 3 studies for buntanetap in early-stage Alzheimer’s patients and agreed on the next steps to advance toward a New Drug Application submission.

The Phase 3 trial will consist of two studies – a 6-month study aimed at confirming buntanetap’s symptomatic benefits and an 18-month study to explore potential disease-modifying effects. Annovis plans to initiate the first trial in Q1 2025, with the possibility of submitting an NDA based on the completion of the 6-month study (https://ibn.fm/Xry8y).

“We are grateful for the FDA’s support in advancing our Phase 3 studies in early AD patients as planned,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio. “This clearance marks an important step forward as we work to bring buntanetap to patients in need. Our team is preparing to launch the study early next year, and we will provide ongoing updates as we progress towards our goals.”

For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Annovis Bio Inc. ANVS | Leave a comment

D-Wave Quantum Inc. (NYSE: QBTS) Discusses Quantum Optimization, Presents Customer Success Stories at 2024 INFORMS Annual Meeting

  • D-Wave’s Vice President of Quantum Technology Evangelism, Murray Thom, was a featured speaker at the event’s Technology Showcase, detailing how D-Wave quantum technologies can tackle complex optimization problems.
  • D-Wave’s Staff Technical Advisor Catherine Potts led an exhibitor workshop covering the fundamentals of quantum computing and demonstrated real-world cases.
  • Participants were given the opportunity to explore D-Wave’s Leap(TM) real-time quantum cloud service, which features a portfolio of hybrid solvers able to deal with problems involving millions of variables and constraints.
  • The 2024 INFORMS Annual Meeting was expected to attract 6,000 attendees, including members, students, prospective employers and employees, as well as academic and industry experts.

D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, recently participated in the 2024 INFORMS Annual Meeting, highlighting its quantum optimization solutions and customer success stories.

INFORMS is the largest professional association for the decision and data sciences, encompassing a diverse range of academic and industry experts in operations research, analytics, management science, economics, behavioral science, statistics, artificial intelligence, data science, applied mathematics, and more. The 2024 INFORMS Annual Meeting, held October 20-23 in Seattle, Washington, was expected to be attended by more than 6,000 members, students, prospective employers and employees, and academic and industry experts.

In line with the INFORMS theme of “Smarter Decisions for a Better World,” D-Wave was a featured speaker at the event’s Technology Showcase. D-Wave hosted an exhibitor workshop sharing the fundamentals of quantum computing (https://ibn.fm/zSW3q), held live product demonstrations, and highlighted customer use cases that showed how quantum technology can surpass classical computer solvers to address real-world complexities for better answers and accelerated time-to-solution.

D-Wave Staff Technical Advisor Catherine Potts led an exhibitor workshop covering the fundamentals of quantum computing and how businesses can quickly get started. She demonstrated real-world applications through use case examples.

Murray Thom, D-Wave’s vice president of quantum technology evangelism, presented during the Technology Showcase, detailing how the company’s quantum technologies can successfully tackle complex optimization problems such as scheduling large workforces, managing production lines, and routing fleets of vehicles.

Company recruiters attended the event’s career fair to highlight what it’s like to work in the field of quantum optimization and at D-Wave specifically, meeting with potential candidates for open roles.

To further promote the adoption of annealing quantum technology, D-Wave offered attendees the opportunity for a free consultation to help them determine whether quantum optimization could improve the quality of results and accelerate time-to-solution for their most pressing problems, with one organization to be selected for a complimentary proof-of-technology project.

For more information, visit the company’s website at www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker with FDA Leadership

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently announced an upcoming meeting with U.S. Food and Drug Administration (“FDA”) leadership. The focus is to discuss Clene’s CNM-Au8® biomarker and related clinical and survival data for ALS. “FDA’s Director of the Office on New Drugs, the Director of the Office of Neuroscience, and the Division of Neurology 1 (‘DN1’) review team, as well as recognized key opinion leaders in ALS, biostatistics and biomarkers,” will attend the meeting according to a recent article.

“Clene looks forward to the opportunity to have experts present their views to the FDA and address questions on ALS biomarkers, related clinical endpoints and survival data, all of which Clene believes are essential for the understanding of its CNM-Au8,” the company stated in a news release. Clene also voiced appreciation for the FDA’s use of process and regulatory flexibility to obtain the best outcome for people living with ALS.

To view the full article, visit https://ibn.fm/S7LBM

About Clene Inc.

Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Clene Inc. CLNN | Leave a comment